GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (NAS:AUPH) » Definitions » Cyclically Adjusted PB Ratio

AUPH (Aurinia Pharmaceuticals) Cyclically Adjusted PB Ratio : 3.42 (As of May. 27, 2025)


View and export this data going back to 2009. Start your Free Trial

What is Aurinia Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2025-05-27), Aurinia Pharmaceuticals's current share price is $8.15. Aurinia Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $2.38. Aurinia Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 3.42.

The historical rank and industry rank for Aurinia Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

AUPH' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.3   Med: 3.57   Max: 21.62
Current: 3.4

During the past years, Aurinia Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 21.62. The lowest was 0.30. And the median was 3.57.

AUPH's Cyclically Adjusted PB Ratio is ranked worse than
71% of 669 companies
in the Biotechnology industry
Industry Median: 1.48 vs AUPH: 3.40

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Aurinia Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2025 was $2.542. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.38 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Aurinia Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Aurinia Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurinia Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Aurinia Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.08 14.54 2.30 4.09 3.89

Aurinia Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.25 2.53 3.22 3.89 3.38

Competitive Comparison of Aurinia Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Aurinia Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aurinia Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Aurinia Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


;
;

Aurinia Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Aurinia Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=8.15/2.38
=3.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aurinia Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Aurinia Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=2.542/129.1809*129.1809
=2.542

Current CPI (Mar. 2025) = 129.1809.

Aurinia Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201506 0.868 100.500 1.116
201509 0.729 100.421 0.938
201512 0.618 99.947 0.799
201603 0.496 101.054 0.634
201606 0.554 102.002 0.702
201609 0.518 101.765 0.658
201612 0.681 101.449 0.867
201703 2.103 102.634 2.647
201706 2.138 103.029 2.681
201709 1.996 103.345 2.495
201712 1.972 103.345 2.465
201803 1.814 105.004 2.232
201806 1.666 105.557 2.039
201809 1.469 105.636 1.796
201812 1.317 105.399 1.614
201903 1.520 106.979 1.835
201906 1.371 107.690 1.645
201909 1.312 107.611 1.575
201912 2.671 107.769 3.202
202003 2.342 107.927 2.803
202006 2.121 108.401 2.528
202009 3.154 108.164 3.767
202012 3.218 108.559 3.829
202103 2.890 110.298 3.385
202106 2.588 111.720 2.992
202109 2.301 112.905 2.633
202112 3.383 113.774 3.841
202203 3.162 117.646 3.472
202206 2.987 120.806 3.194
202209 2.980 120.648 3.191
202212 2.850 120.964 3.044
202303 2.730 122.702 2.874
202306 2.736 124.203 2.846
202309 2.729 125.230 2.815
202312 2.628 125.072 2.714
202403 2.502 126.258 2.560
202406 2.550 127.522 2.583
202409 2.711 127.285 2.751
202412 2.679 127.364 2.717
202503 2.542 129.181 2.542

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Aurinia Pharmaceuticals  (NAS:AUPH) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Aurinia Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aurinia Pharmaceuticals Business Description

Traded in Other Exchanges
Address
14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Executives
Peter Greenleaf director, officer: Chief Executive Officer ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Stephen P. Robertson officer: EVP, General Counsel #1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8
Matthew Maxwell Donley officer: Ex VP, Intern'l Operations 4520 EAST WEST HIGHWAY, 3RD FLOOR, BETHESDA MD 20814
Joseph M Miller officer: Chief Financial Officer C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202
Jeffrey Allen Bailey director BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Karen L. Smith director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Scott Michael Habig officer: Chief Commercial Officer #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Daniel Billen director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
R. Hector Mackay-dunn director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Jayne David R.w. director #1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8
Jill Leversage director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Brinda Balakrishnan director #1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Volker Knappertz officer: EVP, Research and Development SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB249BZ
Robert T Foster director C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Joseph P Hagan director 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037